How does EPA characterize an agents potential for human carcinogenicity under the Guidelines?
The Guidelines recommend that an agent’s human carcinogenic potential be described in a weight-of-evidence narrative. The narrative summarizes the full range of available evidence and describes any conditions associated with conclusions about an agent’s hazard potential. For example, the narrative may explain that an agent appears to be carcinogenic by some routes of exposure but not others (e.g., by inhalation but not ingestion). Similarly, a hazard may be attributed to exposures during sensitive lifestages of development but not at other times. The narrative also summarizes uncertainties and key default options that have been invoked.
Related Questions
- What are the potential uses of human stem cells and the obstacles that must be overcome before these potential uses will be realised?
- How does EPA characterize an agents potential for human carcinogenicity under the Guidelines?
- Does an agent have a potential liability for not discussing LTCI with a client?
